The effects of decursinol on various models of sepsis were investigated. Intra-peritoneal pretreatment of mice with various doses of decursinol (1∼ 100 mg/kg) effectively suppressed lethality induced in three mouse models of experimental sepsis, i.e., lipopolysaccharide (LPS)/D-galactosamine (GalN), high-dose LPS (20 mg/kg), and cecal ligation and puncture (CLP). Intra-peritoneal pretreatment of mice with decursinol (50 mg/kg) markedly enhanced the LPS/GalN-induced increase of plasma interleukin-10 (IL-10) levels, without affecting plasma TNF-α , IL-6 and IL-12 levels. These results suggest that decursinol could be effective for prevention or treatment of sepsis.
INTRODUCTION
Severe sepsis is a serious disease accounting for the major of death in intensive care unit. Until now, treatment of severe sepsis is unsatisfactory (Nguyen and Smith, 2007) . In an attempt to find a potential anti-septic agent from plants, we screened crude extracts of oriental medicinal herbs for protecting lipopolysaccharide (LPS)-induced-lethality in D-galactosamine-sensitized mice, and found that orally administered methanol extract of Angelica significantly inhibited the LPS-induced-lethality (unpublished observation). As decursinol (Fig. 1) is a known constituent of Angelica (Ryu et al., 1967) , the effect of decursinol on various mouse models of sepsis was investigated in the present study.
METHODS

Animals and models of sepsis
Five male ICR mice, weighing 23∼28 g, were housed per cage in a room maintained at 22±1 o C with an alternating 12 hour light-dark cycle. Food and water were available ad libitum. Procedures for animal experiments were approved by the Animal Experimentation Committee at Hallym University. For lipopolysaccharide (LPS)/D-galactosamine (GalN)-induced lethality (Galanos et al., 1979) , LPS (Escherichia coli 055：B5, Sigma, USA) was dissolved in phosphate-buffer saline (PBS) at 1 μg/μl and stored at − 80 o C until use. GalN (ICN, USA) was dissolved in PBS at 0.16 g/ml and added to 7.2 μl LPS. The LPS/GalN mixture was used immediately. Each mouse received LPS/GalN (LPS 36 μg/kg, GalN 0.8 g/kg) intra-peritoneally (i.p.) at a volume of 1 ml/100 g of body weight. Decursinol was dissolved in 10% DMSO, and was administered i.p. 30 min prior to i.p. injection of LPS/GalN. For high dose LPSinduced lethality, various doses (1∼100 mg/kg) of decursinol were administered i.p. 30 min prior to i.p. injection of LPS (20 mg/kg). For cecal ligation & puncture (CLP) , mice were anaesthetized with pentobarbital (50 mg/kg, i.p.), and a small abdominal midline incision was made and the cecum was exposed. The cecum was mobilized, ligated below the ileocecal valve, and punctured through both surfaces two with a 22-gauge needle, and the abdomen was closed. Mice subjected to sham-CLP underwent the same procedure as above except for ligation and puncture of the cecum. Various doses (2, 10, 50 mg/kg) of decursinol were administered i.p. at 2 h and 4 h after CLP. 
Cytokine measurements
Mice were i.p injected with decursinol (50 mg/kg) or vehicle (10% DMSO) at 30 min before i.p. injection of LPS/GalN. Blood was collected from the retro-orbital venous plexus at 1.5 h after LPS/GalN administration and centrifuged at 4,000 g at −4 o C for 15 min. Plasma sample was stored at −20 o C until assayed. Plasma levels of TNF-α, IL-6, IL-10, and IL-12 were measured with an enzyme-linked immunoassay kit (Genzyme, USA). Assays were performed exactly as described by manufacturers.
Statistical analysis
Statistical analysis of survival data was performed by the log-rank test. Cytokine data were evaluated by one-way analysis of variance (ANOVA). Bonferroni and NewmanKeuls tests were used for post-hoc comparisons. p values less than 0.05 were considered to indicate statistical significance.
RESULTS
Protection of mive against LPS/ GalN-, high dose LPS-, and CLP-induced lethality by decursinol
To examine the protective effect of decursinol against LPS/GalN-induced lethality, mice were pretreated with decursinol 30 min before LPS/GalN injection, and lethality was observed for 3 days. As shown in Fig. 2a , treatment of mice with LPS/GalN (i.p.) induced 100% death rate within 24 h. However, intra-peritoneal pretreatment of mice with decursinol (1∼100 mg/kg) dose-dependently protected the animals from LPS/GalN-induced lethality; the lethality began to be significantly improved with the dose of 3 mg/kg, and was completely inhibited at the dose of 100 mg/kg. Next, we examined the effect of decursinol on the high-dose LPS-induced lethality. As shown in Fig. 2b , treatment of mice with high dose of LPS (20 mg/kg, i.p.) induced 71% (5 from 7) death rate in 3 days. However, intra-peritoneal pretreatment of mice with decursinol (100 mg/kg) significantly inhibited the high-dose LPS-induced lethality.
Next, we examined the protective effect of decursinol on lethality which was induced by CLP, a model of septic peritonitis. As shown in Fig. 2c , CLP induced 71% (5 from 7) death rate in 3 days. However, intra-peritoneal treatment of mice twice with decursinol at 2 h and 4 h after CLP significantly inhibited CLP-induced lethality at the dose of 10 mg/kg. Interestingly, decursinol was less effective at the dose of 50 mg/kg than at 10 mg/kg, suggesting that the optimal effective dose of decursinol is lower in CLP model than in LPS model. However, when given twice at 6 h and 8 h after CLP, decursinol showed no protective effect on CLP-induced lethality (data not shown).
Effects of decursinol on LPS/ GalN-induced plasma cytokine levels
Intra-peritoneal injection of LPS/GalN into mice resulted in a marked elevation of plasma TNF-α, IL-6, IL-10, and IL-12 levels, when measured at 1.5 h after LPS/GalN injection. Pretreatment with decursinol (50 mg/kg i.p.) 30 min prior to LPS/GalN injection resulted in a marked augmentation of LPS/GalN-induced plasma levels of IL-10, without affecting LPS/GalN-induced plasma TNF-α, IL-6, and IL-12 levels (Fig. 3) .
DISCUSSION
Decursinol has been shown to have neuroprotective and analgesic effects Choi et al., 2003; Lee et al., 2003) . In the present study, decursinol was shown to have a protective effect on various mouse models of sepsis, i.e. lethality induced by LPS/GalN, high dose-LPS, and CLP. Among various cytokines, decursinol markedly enhanced LPS/GalN-induced plasma IL-10 levels.
IL-10 is an important anti-inflammatory cytokine (Pestka et al., 2004) . Endogenous IL-10 reportedly protects mice from death during septic peritonitis (van der Poll et al., 1995) . Administration of recombinant IL-10 inhibits LPS toxicity in mice (Howard et al. 1993) . Therefore, augmentation of IL-10 levels can be an effective way of treatment or prevention of sepsis (Scumpia and Moldawer, 2005) . In the present study, decursinol was found to markedly augment LPS/GalN-induced plasma IL-10 levels. Therefore, the action of decursinol could be ideal for this purpose. In addition to sepsis, IL-10 has been reported to be beneficial in various other inflammatory diseases, including inflammatory bowel disorders, multiple sclerosis and rheumatoid arthritis (Pestka et al., 2004) . Boosting endogenous IL-10 production has been suggested as an important strategy for treating various inflammatory disorders (Zhou et al. 2005) . Thus, the IL-10 elevating activity of decursinol could be potentially effective in these disorders.
The mechanism of decursinol involved in the increase of IL-10 remains presently unclear. Several classes of agents are known to increase IL-10 levels, including cAMP elevating agents [such as isoproterenol (Suberville et al., 1996) ] and pyrrolidine dithiocarbamate (PDTC), an antioxidant (Nemeth et al., 1998) . However, these agents decrease TNF-α and IL-6, while augmenting of IL-10. Thus, decursinol is different from the above cited agents in that it specifically increases IL-10 levels without altering TNF-α and IL-6. Further studies are needed for elucidating mechanisms involved.
